TearLab Corp (NASDAQ:TEAR)

2.70
Delayed Data
As of 11:45am ET
 +0.10 / +3.85%
Today’s Change
1.50
Today|||52-Week Range
8.18
+1.89%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$87.3M

Company Description

TearLab Corp. is an in vitro diagnostic company, which develops ophthalmic devices. The company commercializes proprietary in vitro diagnostic tear testing platform, the TearLab test for dry eye disease, or DED, which enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. It develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in San Diego, CA.

Contact Information

TearLab Corp.
9980 Huennekens Street
San Diego California 92121
P:(858) 455-6006
Investor Relations:
(647) 872-4849

Employees

Shareholders

Mutual fund holders24.70%
Individual stakeholders14.10%
Other institutional11.82%

Top Executives

Elias VamvakasChairman, Chief Executive Officer & Secretary
Joseph JensenPresident & Chief Operating Officer
William G. DumencuChief Financial Officer & Treasurer
Benjamin D. SullivanChief Scientific Officer
Stephen G. ZminaVice President-Manufacturing & Engineering

To view my watchlist

Not a member yet?

Sign up now for a free account